Abstract
Spinocerebellar ataxia type 7 is a neurodegenerative inherited disease caused by a CAG expansion in the coding region of the ATXN7 gene, which results in the synthesis of polyglutamine-containing ataxin-7. Expression of mutant ataxin-7 disturbs different cell processes, including transcriptional regulation, protein conformation and clearance, autophagy, and glutamate transport; however, mechanisms underlying neurodegeneration in SCA7 are still unknown. Implication of oxidative stress in the pathogenesis of various neurodegenerative diseases, including polyglutamine disorders, has recently emerged. We perform a cross-sectional study to determine for the first time pheripheral levels of different oxidative stress markers in 29 SCA7 patients and 28 age- and sex-matched healthy subjects. Patients with SCA7 exhibit oxidative damage to lipids (high levels of lipid hydroperoxides and malondialdehyde) and proteins (elevated levels of advanced oxidation protein products and protein carbonyls). Furthermore, SCA7 patients showed enhanced activity of various anti-oxidant enzymes (glutathione reductase, glutathione peroxidase, and paraoxonase) as well as increased total anti-oxidant capacity, which suggest that activation of the antioxidant defense system might occur to counteract oxidant damage. Strikingly, we found positive correlation between some altered oxidative stress markers and disease severity, as determined by different clinical scales, with early-onset patients showing a more severe disturbance of the redox system than adult-onset patients. In summay, our results suggest that oxidative stress might contribute to SCA7 pathogenesis. Furthermore, oxidative stress biomarkers that were found relevant to SCA7 in this study could be useful to follow disease progression and monitor therapeutic intervention.
Similar content being viewed by others
References
David G, Abbas N, Stevanin G, Durr A, Yvert G, Cancel G, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet. 1997;17(1):65–70.
David G, Durr A, Stevanin G, Cancel G, Abbas N, Benomar A, et al. Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). Hum Mol Genet. 1998;7(2):165–70.
Enevoldson TP, Sanders MD, Harding AE. Autosomal dominant cerebellar ataxia with pigmentary macular dystrophy. A clinical and genetic study of eight families. Brain. 1994;117(Pt 3):445–60.
Garden GA, La Spada AR. Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum. 2008;7(2):138–49.
Velazquez-Perez L, Cerecedo-Zapata CM, Hernandez-Hernandez O, Martinez-Cruz E, Tapia-Guerrero YS, Gonzalez-Pina R, et al. A comprehensive clinical and genetic study of a large Mexican population with spinocerebellar ataxia type 7. Neurogenetics. 2015;16(1):11–21.
Salas-Vargas J, Mancera-Gervacio J, Velazquez-Perez L, Rodrigez-Labrada R, Martinez-Cruz E, Magana JJ, et al. Spinocerebellar ataxia type 7: a neurodegenerative disorder with peripheral neuropathy. Eur Neurol. 2015;73(3–4):173–8.
David G, Giunti P, Abbas N, Coullin P, Stevanin G, Horta W, et al. The gene for autosomal dominant cerebellar ataxia type II is located in a 5-cM region in 3p12-p13: genetic and physical mapping of the SCA7 locus. Am J Hum Genet. 1996;59(6):1328–36.
van de Warrenburg BP, Frenken CW, Ausems MG, Kleefstra T, Sinke RJ, Knoers NV, et al. Striking anticipation in spinocerebellar ataxia type 7: the infantile phenotype. J Neurol. 2001;248(10):911–4.
McMahon SJ, Pray-Grant MG, Schieltz D, Yates JR 3rd, Grant PA. Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA and SLIK histone acetyltransferase activity. Proc Natl Acad Sci U S A. 2005;102(24):8478–82.
Palhan VB, Chen S, Peng GH, Tjernberg A, Gamper AM, Fan Y, et al. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc Natl Acad Sci U S A. 2005;102(24):8472–7.
Yang H, Liu S, He WT, Zhao J, Jiang LL, Hu HY. Aggregation of Polyglutamine-expanded Ataxin 7 protein specifically sequesters ubiquitin-specific protease 22 and deteriorates its deubiquitinating function in the Spt-Ada-Gcn5-acetyltransferase (SAGA) complex. J Biol Chem. 2015;290(36):21996–2004.
Janer A, Werner A, Takahashi-Fujigasaki J, Daret A, Fujigasaki H, Takada K, et al. SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7. Hum Mol Genet. 2010;19(1):181–95.
Cornelius N, Wardman JH, Hargreaves IP, Neergheen V, Bie AS, Tumer Z, et al. Evidence of oxidative stress and mitochondrial dysfunction in spinocerebellar ataxia type 2 (SCA2) patient fibroblasts: effect of coenzyme Q10 supplementation on these parameters. Mitochondrion. 2017;34:103–14.
Guevara-Garcia M, Gil-del Valle L, Velasquez-Perez L, Garcia-Rodriguez JC. Oxidative stress as a cofactor in spinocerebellar ataxia type 2. Redox Rep. 2012;17(2):84–9.
Klepac N, Relja M, Klepac R, Hecimovic S, Babic T, Trkulja V. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study. J Neurol. 2007;254(12):1676–83.
Miyata R, Hayashi M, Tanuma N, Shioda K, Fukatsu R, Mizutani S. Oxidative stress in neurodegeneration in dentatorubral-pallidoluysian atrophy. J Neurol Sci. 2008;264(1–2):133–9.
Stack EC, Matson WR, Ferrante RJ. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann N Y Acad Sci. 2008;1147:79–92.
Zhou L, Wang H, Wang P, Ren H, Chen D, Ying Z, et al. Ataxin-3 protects cells against H2O2-induced oxidative stress by enhancing the interaction between Bcl-X(L) and Bax. Neuroscience. 2013;243:14–21.
Ajayi A, Yu X, Lindberg S, Langel U, Strom AL. Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible spinocerebellar ataxia type 7 (SCA7) model. BMC Neurosci. 2012;13:86.
Denny-Brown D, Dawson DM, Tyler HR. Handbook of neurological examination and case recording, vol. viii. 3rd ed. Cambridge: Harvard University Press; 1982. 87 p.
Gomez-Coello A, Valadez-Jimenez VM, Cisneros B, Carrillo-Mora P, Parra-Cardenas M, Hernandez-Hernandez O, et al. Voice Alterations in Patients With Spinocerebellar Ataxia Type 7 (SCA7): Clinical-Genetic Correlations. J Voice. 2017;31(1):123 e1–5.
Magana JJ, Gomez R, Maldonado-Rodriguez M, Velazquez-Perez L, Tapia-Guerrero YS, Cortes H, et al. Origin of the spinocerebellar ataxia type 7 gene mutation in Mexican population. Cerebellum. 2013;12(6):902–5.
Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66(11):1717–20.
Schmitz-Hubsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology. 2008;71(13):982–9.
Klockgether T, Lüdtke R, Kramer B, Abele M, Bürk K, Schöls L, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain. 1998;Pt 4:589–600.
el-Saadani M, Esterbauer H, el-Sayed M, Goher M, Nassar AY, Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989;30(4):627–30.
Gerard-Monnier D, Erdelmeier I, Regnard K, Moze-Henry N, Yadan JC, Chaudiere J. Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation. Chem Res Toxicol. 1998;11(10):1176–83.
Bernal A, Mendez JD, Rosado AA. Rapid colorimetric assay for dry weight. Arch Invest Med (Mex). 1981;12(1):83–8.
Hanasand M, Omdal R, Norheim KB, Goransson LG, Brede C, Jonsson G. Improved detection of advanced oxidation protein products in plasma. Clin Chim Acta. 2012;413(9–10):901–6.
Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta. 2003;329(1–2):23–38.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265–75.
Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101(8):1581–90.
Apak R, Guclu K, Ozyurek M, Karademir SE, Altun M. Total antioxidant capacity assay of human serum using copper(II)-neocuproine as chromogenic oxidant: the CUPRAC method. Free Radic Res. 2005;39(9):949–61.
Chang KH, Chen WL, Wu YR, Lin TH, Wu YC, Chao CY, et al. Aqueous extract of Gardenia jasminoides targeting oxidative stress to reduce polyQ aggregation in cell models of spinocerebellar ataxia 3. Neuropharmacology. 2014;81:166–75.
Pacheco LS, da Silveira AF, Trott A, Houenou LJ, Algarve TD, Bello C, et al. Association between Machado-Joseph disease and oxidative stress biomarkers. Mutat Res. 2013;757(2):99–103.
Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med. 2008;45(5):667–78.
Borza LRA. Review on the cause-effect relationship between oxidative stress and toxic proteins in the pathogenesis of neurodegenerative diseases. Rev Med Chir Soc Med Nat Iasi. 2014;118(1):19–27.
Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxidative Med Cell Longev. 2017;2017:2525967.
Chen CT, Green JT, Orr SK, Bazinet RP. Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fat Acids. 2008;79(3–5):85–91.
Floyd RA, Carney JM. Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann Neurol. 1992;32(Suppl):S22–7.
Chondrogianni N, Stratford FL, Trougakos IP, Friguet B, Rivett AJ, Gonos ES. Central role of the proteasome in senescence and survival of human fibroblasts: induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation. J Biol Chem. 2003;278(30):28026–37.
Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med. 2004;37(7):937–45.
Zarkovic N. 4-hydroxynonenal as a bioactive marker of pathophysiological processes. Mol Asp Med. 2003;24(4–5):281–91.
de Assis AM, Saute JAM, Longoni A, Haas CB, Torrez VR, Brochier AW, et al. Peripheral oxidative stress biomarkers in spinocerebellar Ataxia type 3/Machado-Joseph disease. Front Neurol. 2017;8:485.
Acknowledgments
This work was supported by SEP-CONACyT (grant number CB-2015-01-258043) to JJ-M. This study is dedicated to the patients and the members of SCA7-affected families. We also thank Yessica Tapia-Guerrero, Joan Jano-Ito, and César Cerecedo for technical assistance.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
An informed consent form was signed by all subjects prior to examination and the research protocol was approved by the National Rehabilitation Institute (INR, Mexico City) Research and Ethical Committee.
Conflict of Interest
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Torres-Ramos, Y., Montoya-Estrada, A., Cisneros, B. et al. Oxidative Stress in Spinocerebellar Ataxia Type 7 Is Associated with Disease Severity. Cerebellum 17, 601–609 (2018). https://doi.org/10.1007/s12311-018-0947-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12311-018-0947-0